May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Optimizing the Management of Transplant-Ineligible NDMM: Depth and Durability of Response
April 29th 2022Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.
Watch
Venetoclax for Multiple Myeloma: The Phase 3 BELLINI Trial
April 18th 2022Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Shaji Kumar reviews data from his BELLINI clinical trial studying venetoclax paired with bortezomib and dexamethasone for multiple myeloma treatment.
Watch
Venetoclax Monotherapy for the Treatment of Multiple Myeloma
April 16th 2022Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Shaji Kumar, MD, describes the mechanism of action of BCL-2 inhibitor venetoclax and clinical trial data on its efficacy in multiple myeloma.
Watch
Multiple Myeloma Awareness Month: Quadruplet Regimens Create New Outlook for Sequencing Therapy
March 31st 2022The evolving landscape for treating multiple myeloma has seen significant improvement for patients, giving them better options. One of the key regimens added to this landscape is the use of a new quadruplet regimen.
Read More
Part 1: Reviewing Late-Line Options for Relapsed/Refractory Multiple Myeloma
March 30th 2022During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.
Read More
Considerations When Selecting Patients With R/R Myeloma for Cilta-Cel Treatment
March 4th 2022Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.
Watch
Behind the FDA Approval: Cilta-cel for Treatment of Heavily Pretreated R/R Multiple Myeloma
March 3rd 2022In an interview, Jesus Berdeja, MD, discussed the introduction of ciltacabtagene autoleucel into the treatment landscape for relapsed/refractory multiple myeloma, how it may differ from idecabtagene vicleucel, and the future of CAR T-cell use in the space.
Read More